Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Lilly has decided to discontinue the phase 3 development program for baricitinib in adults with active systemic lupus erythematosus. The decision was made based on data from 2 pivotal phase 3 trials, SLE-BRAVE-I (ClinicalTrials.gov Identifier:…